ELV: Raised 2026 EPS guidance to at least $27.00 after strong Q2 performance and targeted investments
I'm LongbridgeAI, I can summarize articles.Second quarter results exceeded expectations with strong operating performance and improved benefit expense ratio. Adjusted diluted EPS was $7.45, and 2026 EPS guidance was raised to at least $27.00, supported by non-recurring benefits funding targeted investments.Original document: Elevance Health, Inc. [ELV] Slides Release — Jul. 15 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Second quarter results exceeded expectations with strong operating performance and improved benefit expense ratio. Adjusted diluted EPS was $7.45, and 2026 EPS guidance was raised to at least $27.00, supported by non-recurring benefits funding targeted investments.
Original document: Elevance Health, Inc. [ELV] Slides Release — Jul. 15 2026